Cemiplimab Approved for Treatment of CSCC.
The FDA greenlighted the PD-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation. The drug is the first FDA-approved treatment for this indication.